The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease.
The chemokine CX3CL1/fractalkine is expressed by neurons as a transmembrane-anchored protein that can be cleaved to yield a soluble isoform. However, the roles for these two types of endogenous CX3CL1 in neurodegenerative pathophysiology remain elusive. As such, it has been difficult to delineate the function of the two isoforms of CX3CL1, as both are natively present in the brain. In this study we examined each isoform's ability to regulate neuroinflammation in a mouse model of Parkinson's disease initiated by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We were able to delineate the function of both CX3CL1 isoforms by using adeno-associated virus-mediated gene therapy to selectively express synthetic variants of CX3CL1 that remain either permanently soluble or membrane bound. In the present study we injected each CX3CL1 variant or a GFP-expressing vector directly into the substantia nigra of CX3CL1(-/-) mice. Our results show that only the soluble isoform of CX3CL1 is sufficient for neuroprotection after exposure to MPTP. Specifically, we show that the soluble CX3CL1 isoform reduces impairment of motor coordination, decreases dopaminergic neuron loss, and ameliorates microglial activation and proinflammatory cytokine release resulting from MPTP exposure. Furthermore, we show that the membrane-bound isoform provides no neuroprotective capability to MPTP-induced pathologies, exhibiting similar motor coordination impairment, dopaminergic neuron loss, and inflammatory phenotypes as MPTP-treated CX3CL1(-/-) mice, which received the GFP-expressing control vector. Our results reveal that the neuroprotective capacity of CX3CL1 resides solely upon the soluble isoform in an MPTP-induced model of Parkinson's disease.
Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida 33612, USA.
Josh M
JM
Morganti
Kevin R
KR
Nash
Bethany A
BA
Grimmig
Sonali
S
Ranjit
Brent
B
Small
Paula C
PC
Bickford
Carmelina
C
Gemma
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage; D000818:Animals; D054428:Chemokine CX3CL1 / Q000172:deficiency / Q000502:physiology* / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D057809:HEK293 Cells; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*; D020033:Protein Isoforms / Q000096:biosynthesis / Q000172:deficiency / Q000627:therapeutic use; D011897:Random Allocation; D012995:Solubility
C515538:CX3CL1 protein, human; D054428:Chemokine CX3CL1; D018696:Neuroprotective Agents; D020033:Protein Isoforms; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine